A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Active:	Yes
Cancer Type:	Colon/Rectal Cancer Lung Cancer Melanoma	NCT ID:	NCT02817633
Trial Phases:	Phase I	Protocol IDs:	4020-01-001 (primary) NCI-2016-01254
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Tesaro Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT02817633

Summary

This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing
protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1
consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the
recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of
TSR-022 in combination with TSR-042 or docetaxel and as monotherapy

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.